



30 November 2005

GIACONDA HOLDS FIRST AGM

Giaconda Limited (ASX: GIA), held its first Annual General Meeting for the year ending June 30, 2005 on November 16, 2005.

Mr. Chris Bilkey, the Chairman of the Board reported that the company is on track having completed its 12 million share offering for \$0.50 per share on the ASX in September and that corporate governance policies had been developed and approved by the Board. He also announced that the audited financial statements showed a net loss of \$905,987. These and more information on the company can be found on the company website at www.giaconda.net.au.

Mr. Patrick Mclean reported that the company plans are being executed with advances in the areas of licensing negotiations, clinical and manufacturing development and regulatory applications, especially for the company's lead product Myoconda. Timing is still on pace for an FDA approval for this product for the US market in 2008. Myoconda will be indicated for patients suffering from moderate to severe Crohn's Disease who have failed conventional therapy. A retrospective analysis of patients treated with Myoconda therapy in **Professor Tom Borody's** practice demonstrated over 95% response (defined as a reduction in Crohn's Disease Activity Index – CDAI – of 70 or more points and a significant reduction in inflammation in the mucosa of the colon) [note 1] with capability of maintaining remission for over nine years. Professor Borody is the Chief Medical officer of Giaconda.

The company's second product for the eradication of resistant *Helicobacter pylori* demonstrated excellent results with over 90% success in patients treated up to four times with previous therapies [Note 2]. Results of this study are expected to be published in the next two months.

Mr. Chris Bilkey and **Professor Tom Borody** were re-elected to the Board during the meeting.

About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, Myoconda® for the treatment of Crohn's Disease and Heliconda® for the treatment of resistant *Helicobacter pylori* infection. Both of these products are ready for Phase III clinical trials, with a Phase IIIa trial already complete for Myoconda.

For more information, please visit www.giaconda.net.au

GIACONDA LIMITED

Suite 1307, Level 13, 370 Pitt Street, Sydney NSW 2000 Phone: [612] 9266 0440 Fax: [612] 9266 0441

email: info@giaconda.net.au

www.giaconda.net.au

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

ISSUED FOR : GIACONDA LIMITED
FOR FURTHER INFORMATION : MS ROSA SURACE, CHIEF OPERATING OFFICER, GIACONDA LIMITED
TEL: (02) 9266 0440 (BUS): www.giaconda.net.au

Comments on Highlighted Text:

1. **"Response"** is a very broad descriptor, capable of misinterpretation. Giaconda should include some quantitative indication of the observed improvement.
2. This is a significant and unqualified statement as to the results of the study. Giaconda must satisfy itself that the statement is correct.

Giaconda should be aware that there appears a real potential that investors may rely on these statements as a positive indication of future earnings potential and so must be careful to ensure that the statements are supportable and not capable of misleading interpretation when compared against the known facts.
